AlzeCure Pharma: €2.5m

Case

02/18/25
AlzeCure Pharma, a Swedish clinical-stage pharma company specializing in innovative treatments for central nervous system (CNS) disorders, has been awarded a €2.5 million grant from the European Innovation Council (EIC) Accelerator under the Horizon Europe program. In addition, the company has the potential to receive additional equity financing through the EIC Fund, subject to further due diligence and conditions being met. This funding represents a significant milestone in the company’s mission to bring disease-modifying therapies for Alzheimer’s disease (AD) to market. 

"We are honored to receive this prestigious funding from the EIC Accelerator, which recognizes ACD856's groundbreaking potential. This support will accelerate our clinical development and bring us closer to delivering a transformative therapy for Alzheimer's patients. The expertise and dedication of GAEU Consulting were instrumental in securing this highly competitive funding, guiding us through the intricate application process with unparalleled professionalism. Their strategic approach and deep knowledge of the EIC Accelerator framework have been invaluable, and we highly recommend GAEU Consulting to any company seeking to navigate the complexities of European funding opportunities."

- Martin Jönsson, CEO of AlzeCure Pharma